Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (26534)	11/16/1998 3:12:00 PM
From: Wallace Rivers	Read Replies (1) \| Respond to of 32384

What the heck is going on! They can't open this by now?! This isn't a stock which has acted like Avtel (AVCO) did the other day. Not that I intend to trade my shares (unless there is some ridiculous spike up), but it would only be fair and good business practice for the NASDAQ to reopen LGND.

To: WTDEC who wrote (26534)	11/16/1998 3:17:00 PM
From: Andrew H	Respond to of 32384

Monday November 16, 1:12 pm Eastern Time U.S. panel backs vitamin gel for Kaposi's sarcoma SILVER SPRING, Md., Nov 16 (Reuters) - The Food and Drug Administration (FDA) should approve a new topical drug to fade and reduce disfiguring skin lesions caused by Kaposi's sarcoma, a cancer in patients with AIDS, an advisory panel recommended on Monday. Panretin, made by Ligand Pharmaceuticals (Nasdaq:LGND - news) of San Diego, Calif., is a gel form of a Vitamin A derivative called retinoic acid. The FDA usually follows its panels' advice but does not have to. The panel voted 8-1 to recommend approving the drug for marketing in the United States, despite some reservations. Ligand said getting rid of Kaposi's sarcoma lesions might help prevent the cancer's spread to internal organs, but it offered no specific proof. Some panelists, including an AIDS patient, questioned whether the cosmetic benefit was worth the risks of side effects, which can include rash and pain. ''To replace that disfiguring lesion with a large red mark that lasts two to six weeks with pain -- I don't think it's worth it,'' said panelist Michael Marco, who has AIDS. -------------------------------------------------------------------------------- More Quotes and News: Ligand Pharmaceuticals Inc (Nasdaq:LGND - news) Related News Categories: health, US Market News